Bristol’s Bold Projections Grow Bolder As Confidence In R&D Programs Rises
New And Existing Blockbusters Expected To Fill Future Revenue Gaps
Loss of exclusivity for key Bristol Myers Squibb products, starting with top seller Revlimid, is looming over the company’s R&D pipeline. BMS believes its late-stage and newly approved products will generate more than $25bn in sales by 2029.
You may also be interested in...
Chief commercialization officer Chris Boerner said BMS plans to replace Otezla as the oral standard of care for moderate-to-severe psoriasis with Sotyktu (deucravacitinib); its list price is about 40% higher than Amgen’s product.
Bristol already is training cardiologists at major treatment centers in how to treat obstructive hypertrophic cardiomyopathy with Camzyos (mavacamten) based on the REMS in the US label.
The company will present detailed data in the future, but top-line results show statistically significant improvement over placebo at 12 weeks in ulcerative colitis, an increasingly competitive market.